Did you know: 85% of clinical failures are of biological origin and attributable to secondary targets? Classical in-silico approaches focus on the relationship between a pharmaceutical candidate and its target, but do not consider secondary interactions.
Bionext helps decipher and identifies such secondary targets based on structural knowledge of one of them within any kind of ligand-target (protein, RNA/DNA) interaction. Select the best drug candidates or repurposing possibilities, use BioSigh